AUTL – autolus therapeutics plc - american depositary shares (US:NASDAQ)

News

Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 [Yahoo! Finance]
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics (NASDAQ:AUTL) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com